HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hunninghake, D. B. Search for Related Content PubMed PubMed Citation Articles by Hunninghake, D. B.

Cardiovascular Disease in Chronic Obstructive Pulmonary Disease

AstraZeneca LP, Wilmington, Delaware

Correspondence and requests for reprints should be addressed to Donald B. Hunninghake, M.D., U.S. Medical Affairs, Field Medical, AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19850. E-mail: donald.hunninghake{at}astrazeneca.com

Smoking is a major cause of chronic obstructive pulmonary disease (COPD) and cardiovascular disorders, including coronary heart disease (CHD) and peripheral arterial disease. Smoking-induced inflammation and other risk factors like dyslipidemia cause vascular endothelial damage via oxidative stress, and a vicious cycle with the characteristics of atherosclerosis ensues. Inflammatory cytokines stimulate hepatic acute-phase protein production, and C-reactive protein is now used widely to assess inflammation in the arterial wall. Smoking is associated with many alterations in lipids and lipoproteins, and is also prothrombotic. Global risk assessment, which determines the absolute risk for developing CHD in 10 years, is used widely to determine who should receive lipid-lowering therapy. Major CHD risk factors include age, sex, smoking, blood pressure, lipoproteins, and cholesterol, but COPD is not among them. Future studies should determine the absolute risk for developing CHD in patients with COPD. The 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are used widely to treat and prevent cardiovascular disease. The statins may also produce other beneficial pleiotropic effects, including increased nitric oxide and prostacyclin, antithrombosis, and decreased inflammation, perhaps indicating utility in the therapy for COPD. Efforts are currently underway to determine if such antiinflammatory effects are independent of or in addition to simply lowering low-density lipoprotein cholesterol.

Key Words: cardiovascular disease • cholesterol • COPD • statin • therapy

This article has been cited by other articles:

				R P Young, R Hopkins, and T E Eaton Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence Postgrad. Med. J., August 1, 2009; 85(1006): 414 - 421. [Abstract] [Full Text] [PDF]

				G. S. Gilmartin, R. Tamisier, M. Curley, and J. W. Weiss Ventilatory, hemodynamic, sympathetic nervous system, and vascular reactivity changes after recurrent nocturnal sustained hypoxia in humans Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H778 - H785. [Abstract] [Full Text] [PDF]

				J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz Cardiac Disease in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 543 - 548. [Abstract] [Full Text] [PDF]

				R. P. Young, R. Hopkins, and T. E. Eaton Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes Eur. Respir. J., October 1, 2007; 30(4): 616 - 622. [Abstract] [Full Text] [PDF]

				T. H. Thatcher, S. B. Maggirwar, C. J. Baglole, H. F. Lakatos, T. A. Gasiewicz, R. P. Phipps, and P. J. Sime Aryl Hydrocarbon Receptor-Deficient Mice Develop Heightened Inflammatory Responses to Cigarette Smoke and Endotoxin Associated with Rapid Loss of the Nuclear Factor-{kappa}B Component RelB Am. J. Pathol., March 1, 2007; 170(3): 855 - 864. [Abstract] [Full Text] [PDF]